Clinical Trial Update: Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety and dosimetry of Lutathera (lutetium-177 DOTATATE) in adolescent patients with gastroenteropancreatic neuroendocrine tumors and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Tumor
• Paraganglioma
• Pheochromocytoma

Drugs mentioned

• LUTATHERA (Lutetium Lu-177 dotatate)

Snippet

Sponsor: Advanced Accelerator Applications | Conditions: Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-11-27